Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

AbbVie also discussed trials of tavapadon in Parkinson’s disease, which met the primary endpoint in the pivotal Phase III TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...